Pertussis acellular vaccine - GlaxoSmithKline

Drug Profile

Pertussis acellular vaccine - GlaxoSmithKline

Latest Information Update: 28 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pertussis

Most Recent Events

  • 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 24 Oct 2000 PowderJect Pharmaceuticals has acquired Medeva's vaccines business from Celltech and renamed it as Evans Vaccines
  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top